Non-Dopaminergic Neurotransmitter Degeneration as Upstream Driver in Parkinson's Disease
Overview
Traditional models of Parkinson's disease (PD) pathogenesis have focused primarily on dopaminergic neuron loss in the substantia nigra pars compacta (SNc) as the central driver of motor symptoms. However, accumulating evidence demonstrates that non-dopaminergic neurotransmitter systems undergo degeneration earlier and independently of dopaminergic pathology, contributing significantly to non-motor symptoms and potentially representing upstream drivers of disease progression.
This page validates the hypothesis that noradrenergic, serotonergic, cholinergic, and GABAergic systems degenerate as upstream drivers in PD, not merely as downstream consequences of dopaminergic loss.
The Multi-System Neurodegeneration Model
Mermaid diagram (expand to render)
Evidence for Non-Dopaminergic Systems as Upstream Drivers
Temporal Pattern of Degeneration
Postmortem studies reveal that non-dopaminergic neuron loss often precedes dopaminergic degeneration in PD:
| System | Brain Region | Degeneration Timing | Key Symptoms |
|--------|-------------|---------------------|---------------|
| Noradrenergic | Locus coeruleus (LC) | Early/subclinical | Orthostatic hypotension, depression, RBD |
| Serotonergic | Dorsal raphe nucleus (DRN) | Early | Depression, anxiety, sleep disturbance |
| Cholinergic | Pedunculopontine nucleus (PPN) | Early-mid | Gait freezing, postural instability |
| Cholinergic | Nucleus basalis of Meynert (NBM) | Mid-late | Cognitive impairment, attention deficits |
| GABAergic | Striatum, globus pallidus | Variable | Motor rigidity, dyskinesias |
Noradrenergic System (Locus Coeruleus)
The locus coeruleus is among the earliest brain regions affected in PD, with some studies suggesting degeneration before SNc involvement:
Pathological Evidence:
- Severe loss of noradrenergic neurons in PD (up to 80% reduction) [@kalia2005]
- Neurofibrillary tau pathology in LC correlates with disease duration
- Alpha-synuclein pathology in LC follows Braak staging
Functional Consequences:
- Orthostatic hypotension: Loss of sympathetic vasoconstrictor tone
- Cognitive impairment: Noradrenergic modulation of prefrontal cortex
- Depression: Dysregulation of mood circuitry
- REM sleep behavior disorder (RBD): LC involvement in REM atonia
Imaging Evidence:
- Reduced norepinephrine transporter (NET) binding in LC [@hilker2009]
- MIBG scintigraphy shows reduced cardiac sympathetic innervation
Serotonergic System (Dorsal Raphe Nucleus)
The dorsal raphe nucleus (DRN) shows significant degeneration in PD:
Pathological Evidence:
- 30-60% loss of serotonergic neurons in PD
- Correlation between raphe pathology and depression severity
- Serotonergic neurons can take up levodopa and convert to dopamine ectopically
Functional Consequences:
- Depression: Up to 50% of PD patients experience depression
- Anxiety disorders: Comorbid anxiety in PD
- Sleep architecture disturbances: Altered serotonin rhythms
- Motor fluctuations: Ectopic dopamine from serotonergic neurons contributes to dyskinesias
Imaging Evidence:
- Reduced serotonin transporter (SERT) binding in basal ganglia [@pavese2006]
- PET shows decreased 5-HT1A receptor binding in raphe
Cholinergic System
Cholinergic degeneration occurs in two key nuclei:
Pedunculopontine Nucleus (PPN)
- Critical for gait initiation and postural control
- Cholinergic neuron loss correlates with PIGD (postural instability/gait difficulty) phenotype
- Deep brain stimulation of PPN has been explored for gait dysfunction
Nucleus Basalis of Meynert (NBM)
- Primary source of cortical acetylcholine
- Degeneration correlates with cognitive impairment in PD
- Lewy body pathology in NBM parallels cortical involvement
GABAergic System
Gamma-aminobutyric acid (GABA) signaling is dysregulated in PD:
Changes in PD:
- Altered GABA levels in substantia nigra and globus pallidus
- Reduced GABAergic interneuron function in striatum
- Contributes to motor rigidity and bradykinesia
iPSC-Derived Neuron Vulnerability Studies
Induced pluripotent stem cell (iPSC) studies have revealed intrinsic vulnerabilities in non-dopaminergic neurons:
Noradrenergic Neuron Vulnerability
- iPSC-derived locus coeruleus neurons show increased alpha-synuclein aggregation
- Mitochondrial dysfunction is more pronounced in LC neurons than dopaminergic neurons
- Calcium handling abnormalities precede visible pathology
Serotonergic Neuron Vulnerability
- Patient-derived serotonergic neurons demonstrate impaired axonal transport
- Increased sensitivity to oxidative stress
- Reduced serotonin synthesis capacity
Cholinergic Neuron Vulnerability
- iPSC cholinergic neurons show selective vulnerability to alpha-synuclein toxicity
- Synaptic dysfunction occurs early in disease modeling
- Mitochondrial bioenergetic deficits
CSF Biomarker Development
Cerebrospinal fluid biomarkers for non-dopaminergic systems are under development:
Serotonergic Biomarkers
| Biomarker | Abbreviation | Clinical Relevance |
|-----------|--------------|-------------------|
| 5-Hydroxyindoleacetic acid | 5-HIAA | Primary serotonin metabolite; reduced in PD with depression |
| Tryptophan | TRP | Precursor to serotonin; altered metabolism in PD |
| Serotonin | 5-HT | Direct measurement challenging due to low concentrations |
Noradrenergic Biomarkers
| Biomarker | Abbreviation | Clinical Relevance |
|-----------|--------------|-------------------|
| 3-Methoxy-4-hydroxyphenylglycol | MHPG | Primary norepinephrine metabolite; correlates with autonomic dysfunction |
| Epinephrine | EPI | Peripheral sympathetic activity marker |
| Dopamine-beta-hydroxylase | DBH | Enzyme converting dopamine to norepinephrine |
Cholinergic Biomarkers
| Biomarker | Clinical Relevance |
|-----------|-------------------|
| Acetylcholine | Direct measurement challenging; reflects cholinergic tone |
| Choline | Released during ACh breakdown; marker of cholinergic activity |
| Acetylcholinesterase activity | Enzyme activity correlates with cholinergic integrity |
Emerging Biomarker Panels:
- Multi-analyte panels combining neurotransmitter metabolites
- Neurofilament light chain (NfL) as general neurodegeneration marker
- Alpha-synuclein seed amplification assays (SAAs)
PET Imaging of Non-Dopaminergic Systems
Advanced PET imaging allows visualization of non-dopaminergic neurotransmitter systems:
Noradrenergic Imaging
- ¹¹C-YR-3294: Norepinephrine transporter (NET) ligand
- ¹¹C-OMSB: Peripheral sympathetic marker
- ¹⁸F-fluorodopamine: Sympathetic nerve terminal imaging
Serotonergic Imaging
- ¹¹C-DASB: Serotonin transporter (SERT) binding
- ¹⁸F-MPPF: 5-HT1A receptor imaging
- ¹¹C-raclopride: 5-HT2A receptor (indirect)
Cholinergic Imaging
- ¹¹C-PMP: Acetylcholinesterase (AChE) activity
- ¹¹C-NVIB: Muscarinic receptor imaging
- ¹⁸F-FEOBV: Vesicular acetylcholine transporter
Clinical Trials of Multi-Target Intervention
Rationale for combination therapy targeting multiple neurotransmitter systems:
Noradrenergic + Dopaminergic: Atomoxetine
Rationale: Atomoxetine (a selective norepinephrine reuptake inhibitor) may improve:
- Executive function deficits
- Orthostatic hypotension
- Fatigue
Trial Status: Phase II trials in PD with cognitive impairment (NCT04680966)
Cholinergic Enhancement: Donepezil
Rationale: Donepezil (acetylcholinesterase inhibitor) may improve:
- Cognitive dysfunction in PD
- Gait stability (via cholinergic circuits)
- Attention and working memory
Trial Evidence:
- Rivastigmine is FDA-approved for PD dementia
- Donepezil shows promise in non-dementia PD cognitive impairment
- Combination with dopaminergic therapy appears safe
Multi-Target Approaches
| Combination | Rationale | Status |
|-------------|-----------|--------|
| Atomoxetine + Donepezil | NE + ACh enhancement | Planning |
| Serotonergic + Dopaminergic | Reduce motor fluctuations | Completed |
| GABAergic modulators | Reduce dyskinesias | Phase II |
Therapeutic Implications
Understanding non-dopaminergic systems as upstream drivers has therapeutic implications:
Current Treatments
| Target | Medication | Indication |
|--------|-----------|------------|
| Cholinergic | Rivastigmine | PD dementia |
| Serotonergic | SSRIs | Depression in PD |
| Noradrenergic | Midodrine | Orthostatic hypotension |
Disease-Modifying Implications
Early intervention before dopaminergic degeneration
Combination therapy targeting multiple neurotransmitter systems
Neuroprotective strategies specific to each vulnerable system
Biomarker-driven patient stratificationAdditional Non-Dopaminergic Systems in PD
Glutamatergic System Dysfunction
Excitatory amino acid transmission is altered in PD, contributing to both motor and non-motor symptoms:
Changes in PD:
- Elevated cortical glutamate levels in early PD
- Reduced striatal glutamate transport
- Altered NMDA/AMPA receptor expression in basal ganglia
- Excitotoxicity contributes to dopaminergic and non-dopaminergic neuron loss
Regional Involvement:
- Motor cortex: Hyperexcitability contributes to rigidity and bradykinesia
- Striatum: Altered corticostriatal input affects movement initiation
- Subthalamic nucleus (STN): Increased excitatory drive contributes to motor symptoms
Therapeutic Approaches:
- Amantadine (NMDA antagonist): Reduces dyskinesias
- Ceftriaxone: Increases glutamate transporter expression (experimental)
- riluzole: Reduces glutamate release (limited efficacy in PD)
Histaminergic System
The histaminergic system modulates arousal, attention, and motor control:
Changes in PD:
- Loss of histaminergic neurons in the tuberomammillary nucleus
- Reduced histamine H3 receptor binding in basal ganglia
- Altered wakefulness and sleep-wake cycles
Functional Impact:
- Excessive daytime sleepiness (EDS) in up to 50% of PD patients
- Cognitive fluctuations related to arousal state
- Sleep fragmentation and insomnia
Therapeutic Considerations:
- Histamine H3 receptor antagonists (e.g., pitolisant): Being explored for EDS in PD
- Wakefulness-promoting agents may benefit from histamine modulation
Endocannabinoid System
The endocannabinoid system modulates basal ganglia function and neuroinflammation:
Changes in PD:
- Reduced CB1 receptor expression in basal ganglia
- Altered anandamide and 2-AG levels in CSF
- Dysregulated lipid signaling in substantia nigra
Functional Impact:
- Motor symptom modulation (cannabinoid agonists can worsen bradykinesia)
- Neuroinflammatory regulation
- Pain processing and appetite
Therapeutic Approaches:
- Cannabidiol (CBD): Being studied for anxiety and psychosis in PD
- FAAH inhibitors: Increase endocannabinoid levels (experimental)
- Sativex (nabiximols): THC/CBD combination in trials for PD motor symptoms
Orexin/Hypocretin System
Orexin neurons in the lateral hypothalamus regulate wakefulness and autonomic function:
Changes in PD:
- Loss of orexin-producing neurons in PD
- Reduced CSF orexin-A levels correlate with excessive daytime sleepiness
- Orexin neuron loss correlates with disease duration
Functional Impact:
- Severe daytime sleepiness independent of nocturnal sleep disturbance
- REM sleep behavior disorder (RBD) may relate to orexin dysfunction
- Autonomic instability
Therapeutic Approaches:
- Solriamfetol: Dual dopamine-norepinephrine reuptake inhibitor, FDA-approved for narcolepsy
- Pitolisant: Histamine H3 antagonist, improves wakefulness in PD
Molecular Mechanisms of Non-Dopaminergic Vulnerability
Common Pathogenic Pathways
Non-dopaminergic neurons share several mechanisms that make them vulnerable in PD:
1. Calbindin Expression Patterns:
- Neurons with high calbindin-D28k expression are relatively spared in SNc
- Non-dopaminergic systems (LC, DRN) often have lower calbindin, increasing Ca²⁺ vulnerability
- Calcium-dependent metabolic stress contributes to degeneration
2. Axonal Length and Branching:
- Locus coeruleus neurons have extremely long, branched axons
- High metabolic demand for axonal maintenance
- Axonal transport deficits are early events
3. Pacemaker Activity:
- LC and DRN neurons exhibit autonomous rhythmic firing
- Continuous Ca²⁺ influx through L-type channels
- Mitochondrial stress from sustained energy demand
4. Neuromelanin Accumulation:
- Noradrenergic neurons accumulate neuromelanin
- Pro-oxidant and pro-inflammatory properties
- Increases with age, correlates with vulnerability
Protein Aggregation in Non-Dopaminergic Systems
Alpha-synuclein pathology:
- Braak stages 1-2: LC and DRN involvement before SNc
- Type A (brainstem-predominant): Early LC involvement
- Type B (limbic-predominant): Less LC involvement
- Pattern may predict non-motor symptom progression
Tau co-pathology:
- Progressive supranuclear palsy (PSP) co-pathology in 10-15% of PD
- Corticobasal degeneration (CBD) co-pathology in 5-10%
- Affects non-dopaminergic systems differently
Network-Level Dysfunction
Brain-Wide Network Disruption
Non-dopaminergic degeneration causes wide-spread network dysfunction:
Salience Network (Anterior Cingulate/Insula):
- Noradrenergic and serotonergic inputs regulate salience processing
- Dysfunction contributes to apathy and anhedonia
- Loss of emotional salience of stimuli
Default Mode Network (DMN):
- Cholinergic modulation maintains DMN integrity
- NBM degeneration disrupts DMN activity during rest
- Contributes to cognitive impairment and attentional deficits
Central Autonomic Network:
- Noradrenergic LC provides primary modulation
- Dysfunction causes orthostatic hypotension, constipation
- Contributes to autonomic failure
Connectivity Changes
| Network | Key Nodes | Neurotransmitter Modulation | PD Changes |
|---------|-----------|---------------------------|-------------|
| Basal ganglia | Striatum, GPe, GPi, STN | Dopamine, GABA, Glutamate | Motor dysfunction |
| Salience | ACC, insula | NE, 5-HT, ACh | Apathy, anxiety |
| Default mode | PCC, mPFC | ACh | Cognitive decline |
| Central autonomic | Hypothalamus, amygdala | NE, ACh | Autonomic failure |
| Arousal | Locus coeruleus, hypothalamus | NE, Orexin, histamine | Sleep disorders |
Sex Differences in Non-Dopaminergic Degeneration
Epidemiological Patterns
- Women show higher prevalence of RBD and depression in PD
- Men show earlier autonomic dysfunction and more severe motor symptoms
- Hormonal influences on neurotransmitter systems may explain differences
Neurobiological Mechanisms
Estrogen effects:
- Neuroprotective effects on serotonergic and noradrenergic neurons
- May delay non-dopaminergic symptom onset in women
- Post-menopausal loss of protection may accelerate symptoms
Testosterone effects:
- Modulates dopaminergic system function
- May influence age of onset in men
Clinical Implications:
- Non-motor symptom screening should be sex-tailored
- Hormone replacement therapy may have differential effects
- Sex-specific therapeutic approaches warranted
Research Models for Non-Dopaminergic Systems
Cellular Models
iPSC-derived neurons:
- Patient-derived LC-like neurons: Show alpha-synuclein vulnerability
- Serotonergic neurons from PD patients: Demonstrate impaired axon growth
- Cholinergic basal forebrain neurons: Display tau pathology
- Co-culture systems to model circuit-level dysfunction
Gene expression studies:
- Single-cell RNA-seq of PD postmortem LC, DRN, NBM
- Differentially expressed genes in non-dopaminergic populations
- Identifies pathway-specific vulnerabilities
Animal Models
Toxin models:
- 6-OHDA (noradrenergic lesion): Reproduces non-motor symptoms
- DSP-4 (selective LC toxin): Depression-like behavior
- p-chlorophenylalanine (serotonergic): Anxiety and sleep disruption
Genetic models:
- SNCA transgenic: Shows early LC pathology
- LRRK2 mutations: Non-dopaminergic involvement varies
- GBA mutations: Lysosomal dysfunction in multiple neurotransmitter systems
Human Studies
Neuroimaging:
- NET-PET for noradrenergic imaging
- SERT-PET for serotonergic function
- AChE-PET for cholinergic integrity
- Structural MRI for nucleus volumes
Neurophysiology:
- Pupillometry for LC function
- Heart rate variability for autonomic integrity
- EEG biomarkers for arousal state
Clinical Implications and Management
Diagnostic Significance
Non-dopaminergic dysfunction provides:
Early biomarkers:
- RBD as prodromal marker (LC dysfunction)
- Hyposmia (olfactory bulb involvement)
- Constipation (enteric nervous system)
Disease staging:
- Non-motor symptoms cluster into subtypes
- LC involvement predicts RBD and autonomic dysfunction
- Cholinergic decline predicts cognitive trajectory
Prognostic information:
- Early autonomic dysfunction predicts faster progression
- PIGD phenotype correlates with cholinergic loss
- Cognitive impairment correlates with NBM involvement
Treatment Strategies
Symptomatic approaches:
| System | Target | Agent | Evidence Level |
|--------|--------|-------|----------------|
| Noradrenergic | NET | Atomoxetine | Phase II |
| Noradrenergic | Alpha-2 agonist | Clonidine | Limited |
| Serotonergic | SERT | SSRIs | Standard |
| Cholinergic | AChE | Rivastigmine | FDA-approved |
| Cholinergic | AChE | Donepezil | Off-label |
| Histaminergic | H3 receptor | Pitolisant | Phase III |
| Glutamatergic | NMDA | Amantadine | Standard |
| Cannabinoid | CB1 | CBD | Phase II |
Disease-modifying approaches:
Neuroprotective strategies targeting each vulnerable system:
- Antioxidants (e.g., CoQ10 for mitochondrial support)
- Calcium channel blockers (e.g., isradipine for LC neurons)
- Anti-inflammatory agents
Network-level approaches:
- Transcranial magnetic stimulation (TMS) for cortical modulation
- Deep brain stimulation of non-motor targets (e.g., NBM)
- Vagus nerve stimulation (modulates LC function)
Combination therapy rationale:
- Address multiple neurotransmitter systems simultaneously
- Preserve remaining neurons in each system
- Synergistic effects on symptom management
Cross-Disease Relevance and Mechanistic Overlap
Alpha-Synuclein Across Non-Dopaminergic Systems
The pathological spread of alpha-synuclein follows a predictable pattern affecting multiple neurotransmitter systems:
Braak Staging and Non-Dopaminergic Pathology:
- Stage 1: Olfactory bulb and enteric nervous system
- Stage 2: Lower brainstem nuclei (locus coeruleus, dorsal raphe) — precedes SNc involvement
- Stage 3: Midbrain and basal forebrain (cholinergic nuclei)
- Stage 4: Limbic and cortical areas
Selective Vulnerability by System:| System | Neuron Type | Vulnerability Factors | Pathology Pattern |
|--------|-------------|----------------------|-------------------|
| Locus coeruleus | Noradrenergic | Low calbindin, long axons, pacemaker activity | Early, severe (80% loss) |
| Dorsal raphe | Serotonergic | Pacemaker activity, neuromelanin-like pigments | Early, moderate (30-60% loss) |
| PPN | Cholinergic | Large dendritic fields, calcium buffering | Early-mid |
| NBM | Cholinergic | Cortical projection length | Mid-late |
Network-Level Dysfunction
Non-dopaminergic degeneration disrupts major brain networks:
Salience Network (Anterior Cingulate/Insula):
- Noradrenergic and serotonergic inputs regulate salience processing
- Dysfunction contributes to apathy and anhedonia
- Loss of emotional salience of stimuli
Default Mode Network (DMN):
- Cholinergic modulation maintains DMN integrity
- NBM degeneration disrupts DMN activity during rest
- Contributes to cognitive impairment and attentional deficits
Central Autonomic Network:
- Noradrenergic LC provides primary modulation
- Dysfunction causes orthostatic hypotension, constipation
- Contributes to autonomic failure
iPSC and Genetic Evidence
SNCA mutations (SNCA A53T, duplications):
- Accelerated non-dopaminergic pathology
- Earlier onset of RBD, autonomic dysfunction
- Demonstrates alpha-synuclein burden drives multi-system degeneration
LRRK2 G2019S:
- Typical PD phenotype but variable non-dopaminergic involvement
- More severe autonomic dysfunction in some carriers
GBA mutations:
- Enhanced vulnerability of cholinergic neurons
- Accelerated cognitive decline
- Greater noradrenergic involvement
PINK1 and PARK2 (Parkin):
- Earlier onset RBD in mutation carriers
- Serotonergic neuron involvement documented
- Suggests mitochondrial dysfunction affects multiple systems
Neuroprotective Strategies for Non-Dopaminergic Systems
Calcium Channel Modulation
L-type calcium channels (Cav1.3) drive calcium overload in vulnerable neurons:
- Isradipine: Cav1.3 blocker, tested in Phase 3 for neuroprotection (failed primary endpoint but may benefit specific subpopulations)
- Age-related vulnerability: Calcium dysregulation worsens with age, explaining progressive loss
- Combination potential: Calcium blockade + anti-inflammatory approaches
Antioxidant Strategies
Given elevated oxidative stress in non-dopaminergic neurons:
- Coenzyme Q10: Supports mitochondrial complex I function — trials for early PD
- Vitamin E: Lipid-soluble antioxidant — mixed evidence
- N-acetylcysteine: GSH precursor — being explored for neuroprotection
- MitoQ: Mitochondria-targeted antioxidant
Anti-Inflammatory Approaches
Neuroinflammation accelerates non-dopaminergic degeneration:
- Microglial modulation: CSF1R inhibitors reduce microglial burden
- JAK-STAT inhibition: Reduce cytokine-driven degeneration in LC, DRN neurons
- NLRP3 inhibition: Block inflammasome activation
Neurotrophic Factor Support
Growth factors for specific neurotransmitter systems:
- BDNF (Brain-Derived Neurotrophic Factor): Supports serotonergic and cholinergic neurons
- GDNF (Glial Cell Line-Derived Neurotrophic Factor): Primary support for dopaminergic, but supports other monoamine neurons
- Nerve growth factor (NGF): Cholinergic system specificity (particularly NBM)
- NT-3 (Neurotrophin-3): Noradrenergic neuron support
Diagnostic and Prognostic Biomarkers
Imaging Biomarkers
| Target | Tracer | Information Provided |
|--------|--------|----------------------|
| NET (norepinephrine transporter) | 11C-YR-3294 | LC integrity, noradrenergic function |
| SERT (serotonin transporter) | 11C-DASB | DRN serotonergic function |
| AChE (acetylcholinesterase) | 11C-PMP | Cholinergic terminal density |
| VMAT2 | 11C-DTBZ | Monoamine terminal function |
| TSPO | 11C-PK11195 | Microglial activation burden |
Fluid Biomarkers
| System | Biomarker | Source | Clinical Use |
|--------|-----------|--------|-------------|
| General neurodegeneration | NfL, p-tau181 | CSF, blood | Progression tracking |
| Neurofilament light | NfL | CSF, serum | Non-dopaminergic system burden |
| Cholinergic | AChE activity | CSF | NBM/PPN integrity |
| Serotonergic | 5-HIAA | CSF | DRN function |
| Noradrenergic | MHPG | CSF, urine | LC function |
| Synucleinopathy | α-Synuclein seeding | CSF | Diagnosis, not system-specific |
Clinical Endpoints for Non-Dopaminergic Trials
- Cognitive: MoCA, RBANS, PD-CRS
- Autonomic: SCOPA-AUT, orthostatic BP measurement
- Sleep: Polysomnography for RBD
- Mood: BDI, HAMD, MDS-UPDRS Part I (non-motor)
Future Research Directions
Key Unanswered Questions
Initiation event: What triggers non-dopaminergic degeneration before SNc?
Propagation mechanism: How does alpha-synuclein spread to specific nuclei?
Cell-type specificity: What makes LC neurons most vulnerable?
Compensation: Can remaining non-dopaminergic neurons be protected or replaced?
Biomarker development: Which biomarker best tracks non-dopaminergic progression?Emerging Research Technologies
- Spatial transcriptomics: Maps gene expression within specific nuclei
- Proteomics: Identifies pathway changes in LC, DRN, NBM tissue
- Organoid models: Brain organoids with region-specific differentiation
- In vivo PET/MRI: Longitudinal tracking of non-dopaminergic system integrity
Cross-Links to Related Pages
- [Parkinson Disease](/diseases/parkinsons-disease)
- [Non-Dopaminergic Circuit Dysfunction](/mechanisms/non-dopaminergic-circuit-dysfunction-parkinsons)
- [Locus Coeruleus Degeneration](/mechanisms/locus-coeruleus-degeneration)
- [Serotonergic Dysfunction](/mechanisms/serotonergic-dysfunction)
- [Parkinson's Disease Biomarkers](/biomarkers/parkinsons-disease-biomarkers)
- [Pedunculopontine Nucleus in Parkinson's](/cell-types/pedunculopontine-nucleus-parkinsons)
- [Nucleus Basalis Meynert](/cell-types/nucleus-basalis-meynert)
- [REM Sleep Behavior Disorder](/diseases/rem-sleep-behavior-disorder)
See Also
- [Dopaminergic Neuron Vulnerability](/mechanisms/dopaminergic-neuron-vulnerability)
- [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathology)
- [Parkinson's Disease Mechanisms](/mechanisms/parkinsons-disease-mechanisms)
References
[Benarroch EE, Noradrenergic dysfunction in α-synucleinopathies (2018)](https://pubmed.ncbi.nlm.nih.gov/30552178/)
[Jones LA, et al, Serotonergic dysfunction in Parkinson disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32954912/)
[Bohnen NI, et al, Cholinergic dysfunction in Parkinson disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33850379/)
[Kalia LV, et al, Locus coeruleus in Parkinson disease (2005)](https://pubmed.ncbi.nlm.nih.gov/16211512/)
[Pavese N, et al, Serotonin and dopamine transporter imaging in PD (2006)](https://pubmed.ncbi.nlm.nih.gov/16403539/)
[Hilker R, et al, Noradrenergic imaging in Parkinson disease (2009)](https://pubmed.ncbi.nlm.nih.gov/18538942/)
[Scholtissen B, et al, GABAergic changes in Parkinson disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16526473/)